Axtria White Paper

White Paper


COVID-19 Recession Effects On Pharmaceutical-Related Patient Health Outcomes

This white paper investigates the research framework to model the expected effects on the decline in health outcomes caused by a decrease in the quantity and quality of pharmaceutical utilization due to the economic effects from a deep and long recession. Four effects caused by a deep recession that will adversely affect the utilization of branded/biologic drugs, which in turn, will cause a decrease in patient health outcomes are reviewed: 1) market access, 2) plan control/design, 3) affordability, and 4) government control (state Medicaid). This paper will close by addressing five actions pharma companies need to take in response to these adverse effects on patient health outcomes: 1) understand managed market effects, 2) predict in real-time future local economic conditions, 3) provide information and assistance that will improve long-term patient adherence, 4) create a robust analytical capability to produce actionable business insights in real-time, and 5) develop an efficient data management structure to support analytical capabilities.

Contact us at with any questions.

Get Your Copy!

Suggested Blogs

Let Us Show You What Axtria’s 

Solutions Can Do For You